Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01543763
Recruitment Status : Recruiting
First Posted : March 5, 2012
Last Update Posted : August 26, 2021
Pharmacyclics LLC.
Xynomic Pharmaceuticals, Inc.
GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease
Information provided by (Responsible Party):
Pamela Munster, University of California, San Francisco

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 1, 2024
Estimated Study Completion Date : January 1, 2025